Drugs / Nanodrop®
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04111965 | Dec 2020 → Dec 2021 | dry eye syndrome | Laboratorios Sophia S.A de C.V. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nanodrop | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04111965 ↗ |
| Known as | PRO-176 | “Patients (phase I: n = 25 and phase II: n = 101) were assigned to receive either PRO-176 (Nanodrop®) or Systane Balance® (control)” PMID 37077305 ↗ Apr 2023 |